 VANCOUVER, Washington, July 06, 2021 GLOBE NEWSWIRE -- CytoDyn Inc. OTCQB: CYDY, CytoDyn or the Company, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its drug candidate, leronlimab, has been granted U.S. Patent No. 11,045,546 by the U.S. Patent and Trademark Office USPTO for methods of treating coronavirus infection the Patent. 